Web Analytics

Investor Profile

Forbion

Forbion Netherlands - Naarden
INVESTOR

1 Disclosed Funding Rounds $12,500,000
12 Participating Investments




Forbion was born out of ABN AMRO Capital Life Sciences, the latter being co-founded by Sander Slootweg, Martien van Osch and Bart Bergstein in 2000. Six years later, we transitioned to Forbio

Invested In

Company Date Round Raised
  Seamless Therapeutics March, 17 ,2023 Series A $12,500,000
  Complement Therapeutics April, 18 ,2023 Series A $78,929,000
  AAVantgarde Bio June, 07 ,2023 Series A $65,333,745
  Mariana Oncology September, 08 ,2023 Series B $175,000,000
  Rampart Bioscience October, 25 ,2023 Series A $85,000,000
  Aiolos Bio October, 26 ,2023 Series A $245,000,000
  Engrail Therapeutics March, 20 ,2024 Series B $157,000,000
  Capstan Therapeutics March, 21 ,2024 Series B $175,000,000
  SynOx Therapeutics April, 23 ,2024 Series B $75,000,000
  Pheon Therapeutics May, 21 ,2024 Series B $120,000,000
  Marea Therapeutics June, 20 ,2024 Series A $190,000,000
  Beacon Therapeutics July, 10 ,2024 Series B $170,000,000